Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 ...

Research indicates GLP-1 receptor agonists, like Ozempic, may elevate testosterone levels in men while promoting weight loss. A study presented at ENDO 2025 showed a significant increase in ...

Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity.

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

The Afib-GLP-1 RA link was, meanwhile, arguably greater for people with severe obesity and those with chronic kidney disease (CKD), though both observations fell short of significance for interaction.

Clinically, these findings could encourage healthcare providers to consider GIP/GLP-1 RA drugs as part of a holistic treatment approach for SUDs, especially for patients who also have coexisting ...

“Further studies are needed to elucidate the mechanisms and causality underlying the association between GLP-1 RA use and reduction of VTE risk, and whether these findings extend to patients ...

Combination therapy with GLP-1 RA and thiazolidinedione significantly reduces all-cause mortality and cardiovascular mortality in type 2 diabetes patients. The study found an increased risk of ...